SJ 733

Drug Profile

SJ 733

Alternative Names: (+)-SJ 000557733; SJ-557733; SJ-733

Latest Information Update: 18 Aug 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator St. Jude Childrens Research Hospital
  • Developer Eisai Co Ltd; Medicines for Malaria Venture; QIMR Berghofer Medical Research Institute; St. Jude Childrens Research Hospital
  • Class Antimalarials; Isoquinolines; Small molecules
  • Mechanism of Action Calcium-transporting ATPase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Malaria

Most Recent Events

  • 01 Aug 2016 Phase-I clinical trials in Malaria (In volunteers) in Australia (PO) (NCT02867059)
  • 15 Feb 2016 Eisai Co Ltd and Charles River Laboratories collaborate to develop Malaria therapeutics
  • 01 Feb 2016 Phase-I clinical trials in Malaria in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top